Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling the end of the programme ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...

Women were less likely than men to be treated for relapsing multiple sclerosis (MS), French registry data showed. Women had a ...

Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing ...

The relapsing forms of MS are the most common. Merck in Neurology and Immunology Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in ...

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.

TANZANIA is set to host the 11th Asia-Africa Luminaries Conference, organised by the Merck Foundation, focusing on health ...

Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

20. Merck's BTK inhibitor last December failed to beat off-patent Aubagio on efficacy in MS trials, hitting confidence in the wider drug class. Sanofi on Monday only provided a brief summary of ...